Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Clinical Nutrition · 2025-01 · 44 · 248-258
DOI: 10.1016/j.clnu.2024.11.042 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2025-01. Verfasst von Chao Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricul…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Synbiotics, Probiotics, Blood Glucose. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND AND AIMS: Combining probiotics and prebiotics in synbiotics may present a synergistic approach to improve type 2 diabetes mellitus (T2DM); however, further evidence is required to establish the comparative efficacy of synbiotics versus probiotics. This study aimed to evaluate the effects of Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) and a synbiotic mixture of MN-Gup and galactooligosaccharide (MN-Gup-GOS) on glycemic control in T2DM patients and explore possible mechanisms. METHODS: This randomized, double-blind, placebo-controlled clinical trial assigned 120 T2DM patients, to receive MN-Gup, MN-Gup-GOS, or placebo intervention for 12 weeks. The primary outcome was fasting blood glucose (FBG), with secondary outcomes including hemoglobin A1C (HbA1C), insulin, homeostatic model assessment of insulin resistance (HOMA-IR), inflammatory indicators, oxidative stress indicators, gastrointestinal hormones, gut microbiota, and bile acids (BAs). RESULTS: The median age of the 120 participants was 59 years (interquartile range: 55-62 years), with 40 being men. Compared to baseline, all three groups exhibited significant reductions in FBG. Additionally, the MN-Gup-GOS group demonstrated significant decreases in HbA1c, serum insulin, and HOMA-IR after intervention, whereas no such reductions were observed in the placebo and MN-Gup groups. Regarding the between-group comparisons, the MN-Gup-GOS intervention showed a significantly greater reduction in FBG compared to the placebo (least squares mean difference [95 % CI], -0.69 [-1.29, -0.10] mmol/L, P = 0.022) and MN-Gup (-0.59 [-1.17, -0.01], P = 0.047) group, but not for other indicators of glucose metabolism. Additionally, MN-Gup and MN-Gup-GOS intervention, especially the latter, significantly modified inflammation, oxidative stress, gut microbiota, serum BAs, and GLP-1 levels. Correlation analysis showed significant associations between changes in certain gut microbiota (Bifidobacterium) and BAs (deoxycholic acid and lithocholic acid) with glycemic indicators. CONCLUSIONS: The auxiliary effect of synbiotics MN-Gup-GOS on reducing FBG levels surpassed that of MN-Gup probiotics alone in T2DM patients, potentially attributed to the enhanced modulation of gut microbiota, BAs, and GLP-1 secretion. TRIAL REGISTRATION: This study was registered on the website of www.chictr.org.cn, number ChiCTR2100052187.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing 100193, China.
- Mengniu Hi-Tech Dairy Product Beijing Co., Ltd., Beijing 101100, China.
- Department of Nutrition, The first medical Center of PLA General Hospital, Beijing 100039, China.
- Department of Obstetrics and Gynecology, Columbia University, New York 10032, USA.
- Research Center for Probiotics, China Agricultural University, Beijing 100193, China.
- Research Center for Probiotics, China Agricultural University, Beijing 100193, China; Hebei Engineering Research Center of Animal Product, Langfang 065200, China.
Zitieren
APA
Zhang, C., Zhang, Q., Zhang, X., Du, S., Zhang, Y., Wang, X., Liu, Y., Fang, B., Chen, J., Liu, R., Hao, Y., Li, Y., Wang, P., Zhao, L., Feng, H., Zhu, L., Chen, L., Chen, S., Wang, F., …, & He, J. (2025). Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 44, 248-258. https://doi.org/10.1016/j.clnu.2024.11.042
Vancouver
Zhang C, Zhang Q, Zhang X, Du S, Zhang Y, Wang X, et al. Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition. 2025;44:248-258. doi:10.1016/j.clnu.2024.11.042
BibTeX
@article{Zhang2025,
author = {Zhang, Chao and Zhang, Qi and Zhang, Xiaoxu and Du, Shuang and Zhang, Yong and Wang, Xifan and Liu, Yinghua and Fang, Bing and Chen, Juan and Liu, Rong and Hao, Yanling and Li, Yixuan and Wang, Pengjie and Zhao, Liang and Feng, Haihong and Zhu, Longjiao and Chen, Lishui and Chen, Shuxing and Wang, Fuqing and Jiang, Zhengqiang and Ji, Yuting and Xiao, Ran and Wang, Ran and He, Jingjing},
title = {Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial},
journal = {Clinical Nutrition},
year = {2025},
volume = {44},
pages = {248--258},
doi = {10.1016/j.clnu.2024.11.042}
}
EUVIMED